Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

NCT06174220 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Arrhythmogenic Cardiomyopathy
Arrhythmogenic Right Ventricular Cardiomyopathy

Interventions

DRUG: Tideglusib
DRUG: Placebo

Sponsor

Hamilton Health Sciences Corporation

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]